Standout Papers

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lym... 2018 2026 2020 2023 370
  1. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial (2018)
    Carol Moreno, Richard Greil et al. The Lancet Oncology
  2. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia  (2022)
    Paul M. Barr, Carolyn Owen et al. Blood Advances

Immediate Impact

1 from Science/Nature 47 standout
Sub-graph 1 of 18

Citing Papers

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 Standout
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
5 intermediate papers

Works of Emily Hsu being referenced

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia 
2022 Standout
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
2018 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Emily Hsu 602 96 506 217 28 666
Manit Munshi 516 69 452 232 40 603
Małgorzata Wach 545 115 429 191 34 667
Andrew Lipsky 549 101 390 251 23 671
Marie‐Sarah Dilhuydy 365 88 322 244 29 590
K Merkle 476 177 435 129 23 649
Luciano Levato 429 126 252 184 39 642
A. M. Liberati 464 125 352 155 19 670
Sasanka M. Handunnetti 535 282 482 148 23 712
Elizabeth Bilotti 573 168 451 202 29 814
Alison Morilla 639 173 579 375 26 820

All Works

Loading papers...

Rankless by CCL
2026